Anti-galectin-9 antibodies and uses thereof
AssigneesNew York University, PureTech LYT, Inc.
InventorsShohei KOIDE, George MILLER, Akiko KOIDE, Linxiao CHEN, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.
Claims14
-34. (canceled)
A method of increasing immune responses in a subject, the method comprising administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising an isolated antibody, which binds human galectin-9, wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 22, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 23, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 24 and comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 19, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 20, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 21.
Dependencies are inferred from the claim text.